Literature DB >> 7797777

Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty.

G W Stone1, C L Grines, K F Browne, J Marco, D Rothbaum, J O'Keefe, G O Hartzler, P Overlie, B Donohue, N Chelliah.   

Abstract

OBJECTIVES: The purpose of this study was to examine the incidence and implications of recurrent ischemia after different reperfusion strategies in acute myocardial infarction.
BACKGROUND: The rates and effects of recurrent ischemia after reperfusion with thrombolytic therapy and with primary percutaneous transluminal coronary angioplasty have not been compared.
METHODS: At 12 centers 395 patients presenting within 12 h of the onset of acute myocardial infarction were prospectively randomized to receive recombinant tissue-type plasminogen activator (rt-PA) or primary coronary angioplasty. Sixteen clinical variables were examined by using univariate and multiple logistic regression analysis to identify the predictors of recurrent ischemia. The relation of recurrent ischemic events to patient outcome was analyzed.
RESULTS: Recurrent ischemia developed in 76 patients (19.2%) before hospital discharge, resulting in reinfarction in 18 patients (4.6%) and death in 5 (2.6%). Recurrent ischemia occurred in 56 patients (28.0%) after rt-PA but in only 20 patients (10.3%) after coronary angioplasty (p < 0.0001), directly contributing to a higher rate of death or reinfarction (7.5% vs. 3.1%, p = 0.05), catheterization and revascularization procedures and prolonged hospital stay after thrombolysis. By multivariate analysis, treatment with coronary angioplasty rather than rt-PA was the strongest predictor of freedom from recurrent ischemia. Although the incidence of recurrent ischemia after angioplasty and after rt-PA was similar within the 1st 2 days of admission (9.2% vs. 14.5%, p = 0.11), after hospital day 2 recurrent ischemia occurred in only 2 patients who received primary angioplasty compared with 27 patients who received rt-PA (1.1% vs. 13.5%, p < 0.0001).
CONCLUSIONS: The development of recurrent ischemia adversely affects patient outcome, increasing morbidity, mortality and resource utilization. The much lower rate of recurrent ischemia after primary coronary angioplasty than after rt-PA results in improved survival without reinfarction and allows a shorter, less complicated hospital stay. Given the extremely low rate of recurrent ischemia after hospital day 2, safe early discharge on day 3 after primary coronary angioplasty should be feasible in selected patients with acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797777     DOI: 10.1016/0735-1097(95)00138-p

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Stenting in Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction.

Authors:  Sanjog Kalra; Hemal Bhatt; Ajay J Kirtane
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jan-Mar

Review 2.  ST-elevation acute myocardial infarction in pregnancy: 2016 update.

Authors:  Sahar Ismail; Cynthia Wong; Priya Rajan; Mladen I Vidovich
Journal:  Clin Cardiol       Date:  2017-02-13       Impact factor: 2.882

Review 3.  Cardiogenic shock: therapy and prevention.

Authors:  W L Barry; I J Sarembock
Journal:  Clin Cardiol       Date:  1998-02       Impact factor: 2.882

4.  Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction.

Authors:  Jeffrey S Berger; David L Brown
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 5.  Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling.

Authors:  Alfred W H Stanley; Constantine L Athanasuleas; Gerald D Buckberg
Journal:  Heart Fail Rev       Date:  2004-10       Impact factor: 4.214

6.  Dipyridamole thallium-201 scintigraphy for early risk stratification of patients after uncomplicated myocardial infarction.

Authors:  J Hung; M Moshiri; G N Groom; A A Van der Schaaf; R W Parsons; M E Hands
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

Review 7.  Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

Authors:  L B Barradell; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

8.  Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q).

Authors:  On Topaz; Douglas Ebersole; Johannes B Dahm; Edwin L Alderman; Hooman Madyoon; Kishor Vora; John D Baker; David Hilton; Tony Das
Journal:  Lasers Med Sci       Date:  2007-04-11       Impact factor: 3.161

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.